TY - JOUR
T1 - Malignant head and neck paragangliomas
T2 - Is there an optimal treatment strategy?
AU - Moskovic, Daniel J.
AU - Smolarz, Joseph R.
AU - Stanley, Douglas
AU - Jimenez, Camilo
AU - Williams, Michelle D.
AU - Hanna, Ehab Y.
AU - Kupferman, Michael E.
PY - 2010
Y1 - 2010
N2 - Background. Little is known about management and prognosis for malignant head & neck paragangliomas. We reviewed records of these patients to determine optimal treatment strategies. Methods. We reviewed 113 cases of head & neck paragangliomas treated at our institution from 1970 to 2005. Nineteen patients were included in the study. All had primary surgical treatment at another institution. Metastatic disease was treated with radiation, chemotherapy, or both. Survival and complications were evaluated. P values were determined by Fischer's exact test. Results. All patients treated with chemotherapy and radiation age 40 years had disease progression. Of the patients < 40, two had stable disease; one had regression of disease with treatment. Patients without disease progression had better prognosis and were alive at last follow-up. Conclusions. Clinical benefit was derived from aggressive treatment. However, careful consideration of the risks of observation versus intensive therapy should be undertaken when managing these patients.
AB - Background. Little is known about management and prognosis for malignant head & neck paragangliomas. We reviewed records of these patients to determine optimal treatment strategies. Methods. We reviewed 113 cases of head & neck paragangliomas treated at our institution from 1970 to 2005. Nineteen patients were included in the study. All had primary surgical treatment at another institution. Metastatic disease was treated with radiation, chemotherapy, or both. Survival and complications were evaluated. P values were determined by Fischer's exact test. Results. All patients treated with chemotherapy and radiation age 40 years had disease progression. Of the patients < 40, two had stable disease; one had regression of disease with treatment. Patients without disease progression had better prognosis and were alive at last follow-up. Conclusions. Clinical benefit was derived from aggressive treatment. However, careful consideration of the risks of observation versus intensive therapy should be undertaken when managing these patients.
UR - http://www.scopus.com/inward/record.url?scp=77958111146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958111146&partnerID=8YFLogxK
U2 - 10.1186/1758-3284-2-23
DO - 10.1186/1758-3284-2-23
M3 - Article
C2 - 20863367
AN - SCOPUS:77958111146
SN - 1758-3284
VL - 2
JO - Head and Neck Oncology
JF - Head and Neck Oncology
IS - 1
M1 - 23
ER -